{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T12:01:45Z","timestamp":1781179305161,"version":"3.54.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100001779","name":"Monash University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001779","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s40256-026-00796-7","type":"journal-article","created":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T12:29:40Z","timestamp":1777552180000},"page":"485-495","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Rapid Access Atrial Fibrillation Clinics in Australia \u2013 Modelling Outcomes and Cost\u2013Effectiveness"],"prefix":"10.1007","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5337-8061","authenticated-orcid":false,"given":"Adam C.","family":"Livori","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ansu","family":"Alex","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamrat","family":"Abebe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Simon","family":"Bell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zanfina","family":"Ademi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jedidiah I.","family":"Morton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,30]]},"reference":[{"key":"796_CR1","unstructured":"Van Gelder IC, Rienstra M, Bunting KV, et al. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2024."},{"key":"796_CR2","unstructured":"Australian Institute of Health and Welfare. Heart, stroke and vascular disease: Australian facts. Tech. rep. Canberra: Australian Institute of Health and Welfare, 2023."},{"key":"796_CR3","doi-asserted-by":"publisher","DOI":"10.1159\/000538564","author":"TB Abebe","year":"2024","unstructured":"Abebe TB, Ilomaki J, Livori A, Bell JS, Morton JI, Ademi Z. Current and future cost burden of ischemic stroke in Australia: dynamic model. Neuroepidemiology. 2024. https:\/\/doi.org\/10.1159\/000538564.","journal-title":"Neuroepidemiology"},{"key":"796_CR4","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1177\/1747493019897870","volume":"16","author":"G Lippi","year":"2021","unstructured":"Lippi G, Sanchis-Gomar F, Cervellin G. Global epidemiology of atrial fibrillation: an increasing epidemic and public health challenge. Int J Stroke. 2021;16:217\u201321.","journal-title":"Int J Stroke"},{"key":"796_CR5","unstructured":"Joglar JA, Chung MK, Armbruster AL, et al. 2023 ACC\/AHA\/ACCP\/HRS guideline for the diagnosis and management of atrial fibrillation. J Am College Cardiol. 2023."},{"key":"796_CR6","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1016\/j.hlc.2018.06.1043","volume":"27","author":"D Brieger","year":"2018","unstructured":"Brieger D, Amerena J, Attia J, et al. National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand: Australian clinical guidelines for the diagnosis and management of atrial fibrillation 2018. Heart Lung Circ. 2018;27:1209\u201366.","journal-title":"Heart Lung Circ"},{"key":"796_CR7","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1093\/europace\/euaa253","volume":"23","author":"E Arbelo","year":"2021","unstructured":"Arbelo E, Aktaa S, Bollmann A, et al. Quality indicators for the care and outcomes of adults with atrial fibrillation. Europace. 2021;23:494\u20135.","journal-title":"Europace"},{"key":"796_CR8","doi-asserted-by":"publisher","first-page":"3425","DOI":"10.1016\/j.sapharm.2021.10.008","volume":"18","author":"EC Swart","year":"2022","unstructured":"Swart EC, Good CB, Henderson R, et al. Identifying outcome measures for atrial fibrillation value-based contracting using the Delphi method. Res Social Adm Pharm. 2022;18:3425\u201331.","journal-title":"Res Social Adm Pharm"},{"key":"796_CR9","doi-asserted-by":"publisher","DOI":"10.1093\/europace\/euab303","author":"M Grymonprez","year":"2022","unstructured":"Grymonprez M, Simoens C, Steurbaut S, De Backer TL, Lahousse L. Worldwide trends in oral anticoagulant use in patients with atrial fibrillation from 2010 to 2018: a systematic review and meta-analysis. EP Europace. 2022. https:\/\/doi.org\/10.1093\/europace\/euab303.","journal-title":"EP Europace"},{"key":"796_CR10","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1055\/a-1515-9428","volume":"122","author":"NR Jones","year":"2022","unstructured":"Jones NR, Crawford W, Yang Y, Hobbs FR, Taylor CJ, Petrou S. A systematic review of economic aspects of service interventions to increase anticoagulation use in atrial fibrillation. Thromb Haemost. 2022;122:394\u2013405.","journal-title":"Thromb Haemost"},{"key":"796_CR11","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.hlc.2020.10.023","volume":"30","author":"H Klimis","year":"2021","unstructured":"Klimis H, Von Huben A, Turnbull S, et al. Rapid access arrhythmia clinics (RAACs) versus usual care: improving efficiency and safety of arrhythmia management. Heart Lung Circ. 2021;30:665\u201373.","journal-title":"Heart Lung Circ"},{"key":"796_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.sapharm.2025.03.005","author":"AC Livori","year":"2025","unstructured":"Livori AC, Kuruppumullage R, Simmons M, et al. Evaluating the implementation of a rapid access atrial fibrillation clinic utilising a pharmacist-physician model of care. Res Soc Adm Pharm. 2025. https:\/\/doi.org\/10.1016\/j.sapharm.2025.03.005.","journal-title":"Res Soc Adm Pharm"},{"key":"796_CR13","doi-asserted-by":"publisher","unstructured":"Gillis AM, Burland L, Arnburg Bscn B, et al. Treating the right patient at the right time: an innovative approach to the management of atrial fibrillation. Can J Cardiol. 2008;24(3):195\u20138. https:\/\/doi.org\/10.1016\/0828-282x(08)70583-x.","DOI":"10.1016\/0828-282x(08)70583-x"},{"key":"796_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jstrokecerebrovasdis.2021.105931","author":"C Marquina","year":"2021","unstructured":"Marquina C, Ademi Z, Zomer E, Ofori-Asenso R, Tate R, Liew D. Cost burden and cost-effective analysis of the nationwide implementation of the quality in acute stroke care protocol in Australia. J Stroke Cerebrovasc Dis. 2021. https:\/\/doi.org\/10.1016\/j.jstrokecerebrovasdis.2021.105931.","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"796_CR15","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1007\/s40273-015-0309-4","volume":"33","author":"JF O\u2019Mahony","year":"2015","unstructured":"O\u2019Mahony JF, Newall AT, van Rosmalen J. Dealing with time in health economic evaluation: methodological issues and recommendations for practice. Pharmacoeconomics. 2015;33:1255\u201368.","journal-title":"Pharmacoeconomics"},{"key":"796_CR16","unstructured":"Manipis K, Viney R, De Abreu Louren\u00b8co R, et al. Health technology assessment methods: economic evaluation. Australian health technology assessment methods and policy review. Tech. rep. Canberra, Australia: Australian Government, Department of Health and Aged Care., 2023. http:\/\/www.chere.uts.edu.au."},{"key":"796_CR17","first-page":"214","volume":"8","author":"KA Fox","year":"2022","unstructured":"Fox KA, Virdone S, Pieper KS, et al. GARFIELD-AF risk score for mortality, stroke, and bleeding within 2 years in patients with atrial fibrillation. Eur Heart J. 2022;8:214\u201327.","journal-title":"Eur Heart J"},{"key":"796_CR18","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.117.006703","author":"K Wang","year":"2017","unstructured":"Wang K, Li H, Kwong WJ, et al. Impact of spontaneous extracranial bleeding events on health state utility in patients with atrial fibrillation: results from the ENGAGE AF-TIMI 48 trial. J Am Heart Assoc. 2017. https:\/\/doi.org\/10.1161\/JAHA.117.006703.","journal-title":"J Am Heart Assoc"},{"key":"796_CR19","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.121.024296","author":"R Joundi","year":"2022","unstructured":"Joundi R, Adekanye J, Leung A, et al. Health state utility values in people with stroke: a systematic review and meta-analysis. J Am Heart Assoc. 2022. https:\/\/doi.org\/10.1161\/JAHA.121.024296.","journal-title":"J Am Heart Assoc"},{"key":"796_CR20","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s40273-023-01243-0","volume":"41","author":"R Norman","year":"2023","unstructured":"Norman R, Mulhern B, Lancsar E, et al. The use of a discrete choice experiment including both duration and dead for the development of an EQ-5D-5L value set for Australia. Pharmacoeconomics. 2023;41:427\u201338.","journal-title":"Pharmacoeconomics"},{"key":"796_CR21","unstructured":"Kim J, Neville E, Dalli L, et al. Economic impact of stroke 2024. Tech. rep. Melbourne: Stroke Foundation of Australia, 2024."},{"key":"796_CR22","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.hlc.2023.12.004","volume":"33","author":"C Weber","year":"2024","unstructured":"Weber C, Hung J, Atkins ER, Hickling S, Briffa T, Li I. Long-term pattern and associated costs of re-hospitalisations in patients after index atrial fibrillation admission in Western Australia, 2011\u20132017. Heart Lung Circ. 2024;33:55\u201364.","journal-title":"Heart Lung Circ"},{"key":"796_CR23","unstructured":"Department of Health and Aged Care. Medicare Benefits Schedule (MBS). 2024."},{"key":"796_CR24","unstructured":"Department of Health and Aged Care. Pharmaceutical Benefits Scheme (PBS). 2022."},{"key":"796_CR25","unstructured":"Australian Institute of Health and Welfare. Health system spending on disease and injury. 2023."},{"key":"796_CR26","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1016\/j.jval.2018.01.017","volume":"21","author":"S Wang","year":"2018","unstructured":"Wang S, Gum D, Merlin T. Comparing the ICERs in medicine reimbursement submissions to NICE and PBAC\u2014does the presence of an explicit threshold affect the ICER proposed? Value Health. 2018;21:938\u201343.","journal-title":"Value Health"},{"key":"796_CR27","doi-asserted-by":"publisher","unstructured":"Elliott RA, Putman K, Davies J, and Annemans L. A review of the methodological challenges in assessing the cost effectiveness of pharmacist interventions. Can J Cardiol. 2014. https:\/\/doi.org\/10.1007\/s40273-014-0197-z","DOI":"10.1007\/s40273-014-0197-z"},{"key":"796_CR28","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.sapharm.2022.09.018","volume":"19","author":"AC Livori","year":"2023","unstructured":"Livori AC, Prosser A, Levkovich B. Clinical outcome measures in the assessment of impact of pharmacists in cardiology ambulatory care: a systematic review. Res Soc Adm Pharm. 2023;19:432\u201344.","journal-title":"Res Soc Adm Pharm"},{"key":"796_CR29","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1177\/1715163519851822","volume":"152","author":"YN Al Hamarneh","year":"2019","unstructured":"Al Hamarneh YN, Johnston K, Marra CA, Tsuyuki RT. Pharmacist prescribing and care improves cardiovascular risk, but is it cost-effective? A cost-effectiveness analysis of the Rx- EACH study. Can Pharm J. 2019;152:257\u201366.","journal-title":"Can Pharm J"},{"key":"796_CR30","doi-asserted-by":"publisher","unstructured":"Rush KL, Burton L, Schaab K, and Lukey A. The impact of nurse-led atrial fibrillation clinics on patient and healthcare outcomes: a systematic mixed studies review. Can J Cardiol. 2019. https:\/\/doi.org\/10.1177\/1474515119845198.","DOI":"10.1177\/1474515119845198"},{"key":"796_CR31","doi-asserted-by":"publisher","unstructured":"Harrell FE. Regression modeling strategies with applications to linear models, logistic and ordinal regression, and survival analysis. Second Edition Springer Series in Statistics. Tech. rep. 2015. https:\/\/doi.org\/10.1007\/978-3-319-19425-7. http:\/\/www.springer.com\/series\/692.","DOI":"10.1007\/978-3-319-19425-7"},{"key":"796_CR32","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.119.005969","volume":"13","author":"AF Ozaki","year":"2020","unstructured":"Ozaki AF, Choi AS, Le QT, et al. Real-world adherence and persistence to direct oral anticoagulants in patients with atrial fibrillation: a systematic review and meta-analysis. Circ Cardiovasc Qual Outcomes. 2020;13:E005969.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"796_CR33","doi-asserted-by":"publisher","DOI":"10.1080\/14796678.2024.2433888","author":"AC Livori","year":"2024","unstructured":"Livori AC, Dalli L, Nicholls SJ, Nelson AJ. Defining, measuring, and addressing medication non-adherence in cardiovascular disease. Future Cardiol. 2024. https:\/\/doi.org\/10.1080\/14796678.2024.2433888.","journal-title":"Future Cardiol"},{"key":"796_CR34","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15391","author":"LL Dalli","year":"2022","unstructured":"Dalli LL, Kilkenny MF, Arnet I, et al. Towards better reporting of the proportion of days covered method in cardiovascular medication adherence: a scoping review and new tool TEN- SPIDERS. Br J Clin Pharmacol. 2022. https:\/\/doi.org\/10.1111\/bcp.15391.","journal-title":"Br J Clin Pharmacol"},{"key":"796_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/J.IJCARD.2024.132397","author":"J Ball","year":"2024","unstructured":"Ball J, Mahony E, Nehme E, Voskoboinik A, Hogarty J, Dawson LP, et al. The burden of atrial fibrillation on emergency medical services: a population-based cohort study. Int J Cardiol. 2024. https:\/\/doi.org\/10.1016\/J.IJCARD.2024.132397.","journal-title":"Int J Cardiol"},{"key":"796_CR36","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-020-00999-z","author":"Z Ademi","year":"2021","unstructured":"Ademi Z, Ackerman IN, Zomer E, Liew D. Productivity-adjusted life-years: a new metric for quantifying disease burden. Pharmacoeconomics. 2021. https:\/\/doi.org\/10.1007\/s40273-020-00999-z.","journal-title":"Pharmacoeconomics"},{"key":"796_CR37","unstructured":"Breadon P, Geraghty J, Jones D & Baldwin E. Special treatment: improving Australians\u2019 access to specialist care. Grattan Institute. (2025)."}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-026-00796-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40256-026-00796-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-026-00796-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T11:38:35Z","timestamp":1781177915000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40256-026-00796-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,30]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["796"],"URL":"https:\/\/doi.org\/10.1007\/s40256-026-00796-7","relation":{},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"value":"1175-3277","type":"print"},{"value":"1179-187X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,30]]},"assertion":[{"value":"17 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}},{"value":"JIM was supported by a Heart Foundation Postdoctoral Fellowship (ID: 108269-2024) from the National Heart Foundation of Australia.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"AL Consulting for Sanofi, Boehringer Ingelheim, Novartis. AA, TA, ZA and JIM have no conflicts to declare relevant to this publication. JSB is supported by a National Health and Medical Research Council (NHMRC) Boosting Dementia Research Leadership Fellowship and has received grant funding or consulting funds from the NHMRC, Medical Research Future Fund, Victorian Government Department of Health, Dementia Australia Research Foundation, Yulgilbar Foundation, Aged Care Quality and Safety Commission, Dementia Centre for Research Collaboration, Pharmaceutical Society of Australia, Society of Hospital Pharmacists of Australia, GlaxoSmithKline Supported Studies Programme, Amgen, and several aged care provider organisations unrelated to this work. All grants and consulting funds were paid to the employing institution.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"Adam C. Livori: writing \u2013 original draft, project administration, methodology, investigation, formal analysis, data curation and conceptualisation. Ansu Alex: writing \u2013 review and editing, and data curation. Tamrat Abebe: writing \u2013 review and editing, and data curation. J. Simon Bell: writing \u2013 review and editing, supervision and resources. Zanfina Ademi: writing \u2013 review and editing, supervision and formal analysis. Jedidiah I. Morton: writing \u2013 review and editing, visualisation, validation, vision, methodology, formal analysis and conceptualisation.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"CRediT Authorship Statement"}},{"value":"The individual-level data underlying this article cannot be shared publicly due to privacy reasons. However, the protocol containing all code used to generate this study is available at\n                      \n                      .","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}},{"value":"Ethics approval was obtained from the Grampians Health Ballarat Human Research Ethics Committee (Project no. 107482 LNR\/\/BHSSJOG) and Monash University Human Research Ethics Committee (43967).","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"The protocol containing all code used to generate this study is available at\n                      \n                      .","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":10,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}}]}}